Recent Updates
Recently added Catalysts
VRDN Neutral Sentiment

Viridian Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Key Takeaway: Johnson Fistel, PLLP is investigating potential claims on behalf of Viridian Therapeutics, Inc. investors who suffered losses. The investigation follows Viridian's recent announcement that its REVEAL-1 Phase 3 trial met its primary endpoint with statistically significant results. However, concerns have emerged regarding the company's compliance with federal securities laws, prompting the investigation. Interested investors are encouraged to reach out to Johnson Fistel for more information on potential recovery options.
Price reaction · baseline $18.53 (2026-03-30 close) · hit after-hours · clean, no other VRDN news in the window
day 0 close
+5.6%
day 1
+3.3%
day 3 · peak
-25%

Market Sentiment Analysis

POSITIVE FACTORS

  • Viridian's Phase 3 trial met its primary endpoint with high statistical significance.
  • Responder rates for the treatment groups were significantly higher than for placebo.

CONCERNS & RISKS

  • The investigation raises concerns about potential compliance with federal securities laws.
  • There are indications of investor losses prompting a legal investigation.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+77%
120-day peak, hindsight
Typical move
3.7%
average across 5 past catalysts
Cash runway
~28 mo
Minimal dilution risk
Lead asset
Veligrotug
Phase 3 · Thyroid Eye Disease

Full Press Release Details

SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Viridian Therapeutics, Inc. (NASDAQ: VRDN). The investigation focuses on Viridian’s executive officers and whether investor losses may be recovered under federal securities laws.
What if I purchased Viridian securities?
If you purchased Viridian securities and suffered losses on your investment, join our investigation now: Click here to join the investigation. Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471. There is no cost or obligation to you.
Background of the investigation
On March 30, 2026, Viridian announced topline results from its REVEAL-1 Phase 3 clinical trial. Among other things, the Company reported that the trial met its primary endpoint with high statistical significance. Viridian disclosed proptosis responder rates of approximately 54% for the every-four-week (Q4W) dosing cohort and approximately 63% for the every-eight-week (Q8W) dosing cohort, compared to approximately 18% for placebo at week 24.
In light of this disclosure, Johnson Fistel is investigating whether Viridian Therapeutics complied with the federal securities laws. If you suffered losses from your investment in Viridian stock, contact Johnson Fistel.
About Johnson Fistel, PLLP | Securities Fraud & Investor Rights
Johnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits and also assists foreign investors who purchased shares on U.S. exchanges. To learn more, visit www.johnsonfistel.com.
In 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services, reflecting the firm’s effectiveness in advocating for investors and recovering approximately $90,725,000 for clients in cases where it served as lead or co-lead counsel.
Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.
Johnson Fistel, PLLP
501 W. Broadway, Suite 800
James Baker, Investor Relations – or – Frank J. Johnson, Esq.

Frequently Asked Questions

What is the focus of Johnson Fistel's investigation?

The investigation focuses on Viridian Therapeutics' executive officers and potential recoveries for investor losses under federal securities laws.

How can I join the investigation into Viridian securities?

If you suffered losses from Viridian securities, you can join the investigation by contacting Johnson Fistel at jimb@johnsonfistel.com.

What were the results of Viridian's REVEAL-1 trial?

Viridian's REVEAL-1 trial met its primary endpoint, showing responder rates of 54% and 63% for different dosing cohorts compared to 18% for placebo.

Who can contact Johnson Fistel for more information?

Investors who incurred losses on Viridian stock can contact Jim Baker at (619) 814-4471 or jimb@johnsonfistel.com.

Is there a cost to join the investigation?

There is no cost or obligation to join Johnson Fistel's investigation into Viridian Therapeutics.

Last updated: Mar 31, 2026